Skip to main content
SpringerLink
Log in

Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients

  • Case Report
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Renal dysfunction is a characteristic of many patients with cancer; however, a standard therapy has not been established for stage III or IV non-small-cell lung cancer (NSCLC) complicated with chronic renal failure. Docetaxel has a proven significant activity against NSCLC. This agent is predominantly eliminated by hepatobiliary extraction and is safe in patients with renal failure, including dialysis patients. Docetaxel is, thus, a therapeutic option in that patient population. Here, we report acute tubular nephrotoxicity secondary to docetaxel in NSCLC patients, even in patients with normal renal function. Little is known about tubular nephrotoxicity induced by docetaxel; however, oncologists should be aware of its possibility.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Launay-Vacher V, Etessami R, Janus N et al (2009) Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung 187:69–74

    Article  PubMed  Google Scholar 

  2. Kintzel PE, Dorr RT (1995) Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 21:33–64

    Article  PubMed  CAS  Google Scholar 

  3. Sahni V, Choudhury D, Ahmed Z (2009) Chemotherapy-associated renal dysfunction. Nat Rev Nephrol 5:450–462

    Article  PubMed  CAS  Google Scholar 

  4. Kudoh S, Takeda K, Nakagawa K et al (2006) Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24:3657–3663

    Article  PubMed  CAS  Google Scholar 

  5. Douillard JY, Laporte S, Fossella F et al (2007) Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small-cell lung cancer: meta-analysis of seven randomized clinical trials. J Thorac Oncol 2:939–946

    Article  PubMed  Google Scholar 

  6. Extra JM, Rousseau F, Bruno R et al (1993) Phase I and pharmacokinetics study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53:1037–1042

    PubMed  CAS  Google Scholar 

  7. Shou M, Martinet M, Korzekwa KR et al (1998) Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8:391–401

    Article  PubMed  CAS  Google Scholar 

  8. Mencoboni M, Olivieri R, Vannozzi MO et al (2006) Docetaxel pharmacokinetics with pre- and post-dialysis administration in a hemodialyzed patient. Chemotherapy 52:147–150

    Article  PubMed  CAS  Google Scholar 

  9. Jones BR, Bhalla RB, Mladek J et al (1980) Comparison of methods of evaluating nephrotoxicity of cis-platinum. Clin Pharmacol Ther 27:557–562

    Article  PubMed  CAS  Google Scholar 

  10. Daugaard G, Abildgaard (1989) Cisplatin nephrotoxicity. Cancer Chemother Pharmacol 25:1–9

    Article  PubMed  CAS  Google Scholar 

  11. Kawai Y, Taniuchi S, Okahara S (2005) Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bull 28:1385–1388

    Article  PubMed  CAS  Google Scholar 

  12. Dentino M, Luft FC, Yum M et al (1978) Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 41:1274–1281

    Article  PubMed  CAS  Google Scholar 

  13. Hochegger K, Lhotta K, Mayer G et al (2007) Pharmacokinetics analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer. Nephrol Dial Transplant 22(1):289–290

    Article  PubMed  CAS  Google Scholar 

  14. Riccardi F, Lorenzo GD, Buonerba C et al (2010) Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer. World J Surg Oncol 8:8

    Article  PubMed  Google Scholar 

  15. Goren MP, Pratt CB, Viar MJ et al (1989) Tubular nephrotoxicity during long-term ifosfamide and mesna therapy. Cancer Chemother Pharmacol 25:70–72

    Article  PubMed  CAS  Google Scholar 

  16. Goren MP, Forastiere AA, Wright RK et al (1987) Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity. Cancer Chemother Pharmacol 19:57–60

    Article  PubMed  CAS  Google Scholar 

  17. Kuhn JA, Argy WP, Rakowski TA et al (1980) Nephrotoxicity of cis-diamminedichloroplatinum (II) as measured by urinary β-glucuronidase. Cancer Treat Rep 64:1083–1086

    PubMed  CAS  Google Scholar 

  18. Reece PA, Stafford I, Russell J et al (1986) Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin. J Clin Oncol 4:1392–1398

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None of the authors have any conflicts of interest associated with this study.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Toyonaka Municipal Hospital, 4-14-1 Shibahara-cho, Toyonaka, Osaka, 560-8565, Japan

    Takayuki Takimoto, Tasuku Nakabori, Akio Osa, Satomu Morita, Haruko Terada, Susumu Oseto & Kinya Abe

  2. Department of Surgery, Toyonaka Municipal Hospital, 4-14-1 Shibahara-cho, Toyonaka, Osaka, 560-8565, Japan

    Takashi Iwazawa

Authors
  1. Takayuki Takimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tasuku Nakabori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akio Osa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Satomu Morita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Haruko Terada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Susumu Oseto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takashi Iwazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kinya Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takayuki Takimoto.

About this article

Cite this article

Takimoto, T., Nakabori, T., Osa, A. et al. Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients. Int J Clin Oncol 17, 395–398 (2012). https://doi.org/10.1007/s10147-011-0304-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-011-0304-5

Keywords

Search

Navigation